<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Methods Protoc</journal-id><journal-id journal-id-type="iso-abbrev">Methods Protoc</journal-id><journal-id journal-id-type="publisher-id">mps</journal-id><journal-title-group><journal-title>Methods and Protocols</journal-title></journal-title-group><issn pub-type="epub">2409-9279</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407478</article-id><article-id pub-id-type="pmc">PMC12101346</article-id>
<article-id pub-id-type="doi">10.3390/mps8030051</article-id><article-id pub-id-type="publisher-id">mps-08-00051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Safety and Efficacy of Pressurized Intra-Thoracic Aerosol Chemotherapy in Non-Small Cell Lung Cancer Pleural Carcinomatosis: Preliminary Results of a Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9291-5619</contrib-id><name><surname>Mastromarino</surname><given-names>Maria Giovanna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-mps-08-00051" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8538-1719</contrib-id><name><surname>Aprile</surname><given-names>Vittorio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-mps-08-00051" ref-type="aff">2</xref><xref rid="c1-mps-08-00051" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Elia</surname><given-names>Gianmarco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af2-mps-08-00051" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5706-0974</contrib-id><name><surname>Bacchin</surname><given-names>Diana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-mps-08-00051" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lenzini</surname><given-names>Alessandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-mps-08-00051" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8818-6553</contrib-id><name><surname>Korasidis</surname><given-names>Stylianos</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-mps-08-00051" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ambrogi</surname><given-names>Marcello Carlo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-mps-08-00051" ref-type="aff">1</xref><xref rid="af2-mps-08-00051" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferrari</surname><given-names>Silvia Martina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af2-mps-08-00051" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Fallahi</surname><given-names>Poupak</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-mps-08-00051" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9909-6820</contrib-id><name><surname>Lucchi</surname><given-names>Marco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-mps-08-00051" ref-type="aff">1</xref><xref rid="af2-mps-08-00051" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Albericio</surname><given-names>Fernando</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-mps-08-00051"><label>1</label>Division of Thoracic Surgery, Cardiac, Thoracic and Vascular Department, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy; <email>mgmastromarino@gmail.com</email> (M.G.M.); </aff><aff id="af2-mps-08-00051"><label>2</label>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Via Roma, 56124 Pisa, Italy</aff><aff id="af3-mps-08-00051"><label>3</label>Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma, 56124 Pisa, Italy</aff><author-notes><corresp id="c1-mps-08-00051"><label>*</label>Correspondence: <email>aprilevittorio@gmail.com</email>; Tel.: +39-050995227</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>8</volume><issue>3</issue><elocation-id>51</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>08</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Pleural carcinomatosis (PC) and malignant pleural effusion (MPE) affect up to 20% of patients with non-small cell lung cancer (NSCLC) and are usually synonymous with poor prognosis. Pressurized Intra-Thoracic Aerosol Chemotherapy (PITAC) is a novel and promising technique to control MPE in PC-NSCLC. This pilot study aimed to assess the feasibility, safety, and efficacy of PITAC in terms of palliative pleurodesis and evaluate the local antineoplastic control by analyzing patient-derived primary cell cultures. From January to December 2023, seven patients underwent PITAC with tailored doses of cisplatin and doxorubicin. There were four males and three females, with a median age of 65 (IQR:19) years. No operating room contamination by aerosolized chemotherapeutics was observed. No intraoperative complications occurred, and 30-day mortality was nil. One patient developed a postoperative prolonged air leak. The median chest tube stay was 2 (IQR:2) days, and the median hospital stay was 4 (IQR:2) days. No systemic toxicity nor hypersensitivity to chemotherapeutics were observed. All patients developed effective pleurodesis in 30 days. Cell cultures obtained from biopsy of PC-NSCLC sampled before PITAC formed confluent and monolayer sheets of attached tumor cells, while after 30 min from PITAC, cultures exhibited a significant reduction in the cancer cells&#x02019; growth. Effective pleurodesis was observed three and six months after surgery in all patients. PITAC is a safe and effective technique to control MPE recurrence and might revolutionize loco-regional therapy for PC-NSCLC. Further research should assess its oncological role.</p></abstract><kwd-group><kwd>non-small cell lung cancer</kwd><kwd>pleural carcinomatosis</kwd><kwd>intrathoracic chemotherapy</kwd><kwd>pleurodesis</kwd><kwd>malignant pleural effusion</kwd><kwd>primary cell cultures</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-mps-08-00051"><title>1. Introduction</title><p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide [<xref rid="B1-mps-08-00051" ref-type="bibr">1</xref>]. Due to its tendency to metastasize, pleural carcinomatosis (PC) and malignant pleural effusion (MPE) are present in up to 20% of NSCLC cases [<xref rid="B2-mps-08-00051" ref-type="bibr">2</xref>]. Systemic therapy remains the cornerstone of treatment in advanced stages. However, despite significant advancements in targeted therapy and immunotherapy, most patients with metastatic disease have a poor prognosis [<xref rid="B3-mps-08-00051" ref-type="bibr">3</xref>]. Immunotherapy may help slow disease progression; however, its impact on survival is limited in patients with MPE that is not effectively controlled through appropriate interventions [<xref rid="B2-mps-08-00051" ref-type="bibr">2</xref>]. In such cases, treatment is primarily palliative, aiming to alleviate clinical symptoms [<xref rid="B4-mps-08-00051" ref-type="bibr">4</xref>]. Pleurodesis, which induces adhesion between the pleural layers, is used to prevent MPE recurrence. To date, the most commonly used sclerosing agent is sterile surgical talc (hydrated magnesium silicate) [<xref rid="B5-mps-08-00051" ref-type="bibr">5</xref>]. In recent years, intrapleural perfusion with various chemotherapeutic agents has been explored in an effort to combine antineoplastic effects with traditional pleurodesis [<xref rid="B6-mps-08-00051" ref-type="bibr">6</xref>,<xref rid="B7-mps-08-00051" ref-type="bibr">7</xref>,<xref rid="B8-mps-08-00051" ref-type="bibr">8</xref>]. However, oncological outcomes remain inconsistent, and a standardized approach has yet to be established.</p><p>The use of Hyperthermic Intrathoracic Chemotherapy (HITHOC) is limited in the palliative management of MPE; instead, it is utilized as part of surgery-based multimodal therapy with curative intent to improve local tumor control in primary or secondary malignancies involving serous surfaces [<xref rid="B6-mps-08-00051" ref-type="bibr">6</xref>,<xref rid="B8-mps-08-00051" ref-type="bibr">8</xref>,<xref rid="B9-mps-08-00051" ref-type="bibr">9</xref>].</p><p>In this scenario, Pressurized Intra-Thoracic Aerosol Chemotherapy (PITAC) might represent a novel therapeutic approach [<xref rid="B10-mps-08-00051" ref-type="bibr">10</xref>]. This technique was inherited from abdominal surgery, where it is carried out to treat unresectable peritoneal metastasis (PtM) with promising results in local disease control [<xref rid="B11-mps-08-00051" ref-type="bibr">11</xref>,<xref rid="B12-mps-08-00051" ref-type="bibr">12</xref>]. Theoretically, PITAC could provide both pleurodesis and an antineoplastic effect by delivering a high-pressure aerosolized chemotherapy into the thoracic cavity [<xref rid="B13-mps-08-00051" ref-type="bibr">13</xref>]. Most data on the efficacy of antineoplastic drugs on PC have been obtained through preclinical research on primary cancer cell cultures. Similarly, several studies have shown that in vitro chemosensitivity correlates with clinical responses, suggesting that these cultures could support the development of personalized treatments for patients with advanced-stage NSCLC [<xref rid="B14-mps-08-00051" ref-type="bibr">14</xref>,<xref rid="B15-mps-08-00051" ref-type="bibr">15</xref>].</p><p>We designed a phase II, non-randomized, open-label pilot study with the following objectives:<list list-type="simple"><list-item><label>(a)</label><p>to assess the feasibility, safety, and preliminary efficacy of PITAC, a novel surgical technique that combines the advantages of surgery and intrathoracic chemotherapy, in inducing pleurodesis and reducing MPE recurrence as part of a multimodal, personalized treatment strategy for PC-NSCLC patients;</p></list-item><list-item><label>(b)</label><p>to evaluate the oncological efficacy of aerosolized chemotherapeutic agents in terms of local disease control, by analyzing patient-derived primary cancer cell cultures obtained from PC-NSCLC biopsies before and after PITAC.</p></list-item></list></p></sec><sec id="sec2-mps-08-00051"><title>2. Materials and Methods</title><sec id="sec2dot1-mps-08-00051"><title>2.1. Patients and Study Endpoint</title><p>All patients affected by a confirmed or highly suspected (according to the pre-operative imaging) PC-NSCLC with MPE, requiring a Video-Assisted Thoracoscopic Surgery (VATS) operation with diagnostic and staging intent, relieve symptoms, and induce pleurodesis, were enrolled.</p><p>Eligibility criteria included the following: age between 18 and 80 years; good performance status (Eastern Oncology Cooperative Group (ECOG) score &#x02264; 2) suitable for general anesthesia [<xref rid="B16-mps-08-00051" ref-type="bibr">16</xref>]; survival expectancy &#x0003e; 3 months; liver, renal and cardiopulmonary function parameters within 10% of the normal range; diagnosis of PC-NSCLC (in suspected cases, pathologic confirmation has been obtained by intraoperative frozen section). All enrolled patients were preoperatively discussed in the multidisciplinary tumor board (MTB).</p><p>Exclusion criteria were as follows: stage IVB (multiple extrathoracic metastases in one or more organs), according to the eight edition of TNM classification for lung cancer [<xref rid="B17-mps-08-00051" ref-type="bibr">17</xref>], and intraoperative findings of trapped lung.</p><p>PITAC efficacy was evaluated according to the World Health Organization(WHO)&#x02019;s criteria for the Treatment Response of MPE after surgery [<xref rid="B18-mps-08-00051" ref-type="bibr">18</xref>]:<list list-type="bullet"><list-item><p>Complete Response (CR): no pleural effusion and symptom-free for at least four weeks;</p></list-item><list-item><p>Partial Response (PR): less than 50% effusion recurrence, asymptomatic, no thoracentesis needed within four weeks;</p></list-item><list-item><p>Stable Disease (SD): more than 50% effusion recurrence or unchanged effusion, symptomatic, thoracentesis needed within four weeks;</p></list-item><list-item><p>Progression Disease (PD): more than 25% increase in pleural effusion.</p></list-item></list></p><p>Objective treatment response of MPE after PITAC included CR and PR and was assessed in an outpatient setting 30 days, 3 months, and 6 months after surgery, with chest X-ray and/or computed tomography (CT) scan, planned according to the follow-up (FUP) protocol.</p><p>Intra and perioperative morbidity, according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0) [<xref rid="B19-mps-08-00051" ref-type="bibr">19</xref>], and intraoperative and 30-day mortality were recorded and reported.</p><p>The Institutional Review Board has approved the study. All methods conformed to the principles of the Declaration of Helsinki. Each patient provided written informed consent for collecting, analyzing, and publishing this study&#x02019;s prospectively obtained anonymized data.</p><p>This manuscript was written according to the Consolidated Standards of Reporting Trials (CONSORT) Statement [<xref rid="B20-mps-08-00051" ref-type="bibr">20</xref>]. The CONSORT checklist is available as the <xref rid="app1-mps-08-00051" ref-type="app">Supplemental File S1</xref>.</p><p>The next step of this ongoing phase 2 trial will be the assessment of the oncological efficacy of PITAC at the locoregional level, specifically in terms of local (intrapleural) disease progression, according to the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. This will be evaluated using chest CT scans scheduled 8&#x02013;12 weeks post-surgery, in accordance with routine FUP conducted by a dedicated oncologist, as per international guidelines [<xref rid="B3-mps-08-00051" ref-type="bibr">3</xref>,<xref rid="B21-mps-08-00051" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot2-mps-08-00051"><title>2.2. Medication</title><p>The selection of chemotherapy agents was made according to the available literature on a similar procedure for PtM. Dedicated pharmacologists prepared cytostatic solutions on medical prescription according to the Body Surface Area (BSA), calculated with the Boyd formula [<xref rid="B22-mps-08-00051" ref-type="bibr">22</xref>]. The drug regimen consisted of Cisplatin (Iketon, Milan, Italy) at doses of 10.5 mg/m<sup>2</sup> in 150 mL NaCl 0.9% and Doxorubicin (Pharmacia, Milan, Italy) at doses of 2.1 mg/m<sup>2</sup> in 50 mL NaCl 0.9%.</p></sec><sec id="sec2dot3-mps-08-00051"><title>2.3. Technique</title><p>The patient was positioned in lateral decubitus under general anesthesia with double-lumen intubation. After the insertion of two 12 mm balloon trocars (Applied Medical, Rancho Santa Margarita, CA, USA) into the chest wall (VII intercostal space (ICS) in the mid-axillary line and V ICS in the anterior axillary line, <xref rid="mps-08-00051-f001" ref-type="fig">Figure 1</xref>A,B), a standard thoracoscopy was performed. Balloon trocars were needed to create a closed system and avoid dispersion of chemotherapy aerosol outside the thoracic cavity. After MPE aspiration and lysis of eventual pleural adhesions, multiple parietal pleural biopsies were sampled on macroscopic lesions or random pleural points (<xref rid="mps-08-00051-f001" ref-type="fig">Figure 1</xref>C). A pleural sample was sent for frozen analysis if preoperative diagnosis was unavailable. Only confirmed cases of PC-NSCLC proceeded with PITAC. A dedicated checklist was reviewed to ensure all safety aspects were covered before chemotherapy administration. An intrathoracic pressure of 12 mmHg CO<sub>2</sub> was established, and a CE-certified disposable nebulizer (RegerGmbH, Villingendorf, Germany) was inserted through a trocar and connected to a high-pressure injector (<xref rid="mps-08-00051-f001" ref-type="fig">Figure 1</xref>D). The patient was covered with a sterile drape and all the staff left the operating room (OR) to avoid eventual chemotherapy exposure. Using a remote control, cisplatin and doxorubicin were consecutively aerosolized into the pleural cavity at 0.7 mL/s flow with a maximal upstream pressure of 1.517 &#x000d7; 10<sup>6</sup> Pa (<xref rid="mps-08-00051-f002" ref-type="fig">Figure 2</xref>A). Vital signs and nebulization procedure were remote-controlled, although acceding to the OR should be safe with no inhalation risk given laminar airflow (<xref rid="mps-08-00051-f002" ref-type="fig">Figure 2</xref>B). The system maintained a steady state for 30 min (constant intrathoracic pressure of 12 mmHg CO<sub>2</sub>) to enhance drug penetration. After this period, the staff entered the OR wearing aerosol masks to remove residual toxic aerosol using a closed surgical smoke evacuation system with micro-particle filters (<xref rid="mps-08-00051-f002" ref-type="fig">Figure 2</xref>C,D). Finally, the trocars were removed, and two chest drainages were placed as standard procedure.</p></sec><sec id="sec2dot4-mps-08-00051"><title>2.4. Primary Cell Cultures</title><p>To evaluate the antineoplastic effect of the high-pressure aerosolized chemotherapy, PCs were sampled both before (time-0) and after drugs nebulization (time-30 min after PITAC); these latter pleural biopsies were obtained from the pleura surrounding the previous biopsy. Samples were submitted for primary cell cultures within 30 min from the collection. The areas of necrosis were removed, and solid tissue was minced and reduced to fragments of about 1 mm. In order to digest the collagen and release tumor cells the fragments were incubated in cell culture medium in the presence of collagenase type I at 200 U/mL concentration for one hour [<xref rid="B23-mps-08-00051" ref-type="bibr">23</xref>]. Since primary cell cultures derive from surgical biopsies, to avoid the possible interference in the conducted analysis given by the presence of macrophages, red blood cells and lymphocytes, which are, in general, the main contaminants, all the primary cells were used within 6&#x02013;10 passages. Cells were cultured in RPMI with 2 mM glutamine, 100 U/mL penicillin/100 &#x003bc;g/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA), and 10% fetal bovine serum (FBS) and maintained at 37 &#x000b0;C and 5% CO<sub>2</sub> [<xref rid="B24-mps-08-00051" ref-type="bibr">24</xref>,<xref rid="B25-mps-08-00051" ref-type="bibr">25</xref>].</p><p>In order to assess the reduction in cell growth, it was evaluated by cell number counting [<xref rid="B26-mps-08-00051" ref-type="bibr">26</xref>]. Cells were plated at a density of 13,000 cells/well in 24-well tissue culture plates in complete medium and counted using a hemocytometer.</p></sec><sec id="sec2dot5-mps-08-00051"><title>2.5. Statistical Analysis</title><p>Data were collected and extracted from our prospective institutional database and medical records. Continuous variables were defined as mean (standard deviation, SD) or median (interquartile range, IQR) where appropriate. Categorical variables were expressed as absolute numbers unless stated otherwise. This paper aims to present the preliminary results of a pilot study. Then, given the small number of patients, no comparison analyses were conducted with a control group. Neither survival probability nor predictive factors were evaluated because statistical significance could not be obtained according to the underpowered sample size.</p></sec></sec><sec sec-type="results" id="sec3-mps-08-00051"><title>3. Results</title><p>From January to December 2023, forty patients affected by a confirmed or suspected PC with MPE underwent VATS at our tertiary care university center. Seven patients were enrolled in this study and underwent PITAC procedure following a confirmed diagnosis of PC-NSCLC. The remaining 33 patients had PC associated with other malignancies. All seven enrolled patients had not received any prior local treatments, such as surgery or radiation therapy, before undergoing PITAC. The cohort included four males and three females, with a median age of 65 (IQR:19) years. The pre-operative characteristics of the patients are summarized in <xref rid="mps-08-00051-t001" ref-type="table">Table 1</xref>.</p><p>Six patients had not received prior systemic chemotherapy, while one patient had undergone two cycles of immune checkpoint inhibitors (ICIs) before surgery. Four patients had a previously confirmed diagnosis of PC-NSCLC, whereas in three cases, pleural involvement was confirmed intraoperatively via frozen section analysis. The mean intra-operative pleural effusion volume was 1180.0 (SD: 785.5) mL. The mean operative time was 125.0 (SD: 27.2) minutes. No OR contamination by aerosolized chemotherapeutic drugs was observed.</p><p>PC biopsies were obtained both before and after chemotherapy nebulization. Tumor tissues were used to establish patient-derived primary bi-dimensional (2D) cell cultures of PC-NSCLC. The time 0 cultures formed confluent, primarily monolayer sheets of medium-sized attached tumor cells (<xref rid="mps-08-00051-f003" ref-type="fig">Figure 3</xref>A). In contrast, time 30 min after PITAC cultures showed a significant reduction in cancer cell growth (<xref rid="mps-08-00051-f003" ref-type="fig">Figure 3</xref>B).</p><p>No major or minor intraoperative complications occurred, and there was no 30-day mortality. One patient developed a prolonged post-operative air leak, resulting from intraoperative adhesiolysis required to release a trapped lung; this was managed conservatively with chest tube drainage for 10 days. No postoperative complications were observed in the remaining six patients. The median chest tube length was 2 (IQR:2) days, and the median hospital stay was 4 (IQR:2) days.</p><p>No systemic toxicity or hypersensitivity to chemotherapeutic agents was observed during hospitalization or throughout early and mid-term FUP. Pathological examination confirmed pleural metastases from lung adenocarcinoma in all patients. Immunohistochemical and molecular characteristics are summarized in <xref rid="mps-08-00051-t002" ref-type="table">Table 2</xref>.</p><p>All patients developed effective pleurodesis within 30 days, as confirmed by serial post-operative chest X-rays. According to the WHO Criteria for the Treatment Response of MPE after surgery, five patients demonstrated a CR, and two showed a PR. The same responses were maintained at 3 and 6 months postoperatively, with effective pleurodesis observed in the entire cohort throughout the FUP period. All patients received postoperative first-line systemic therapy: four were treated with platinum-based chemotherapy combined with ICIs; two patients with EGFR mutation received Tyrosine Kinase Inhibitor (TKI) therapy; and the one patient who had received two cycles of ICIs prior to surgery continued with immunotherapy (<xref rid="mps-08-00051-t003" ref-type="table">Table 3</xref>).</p><p>After a median FUP of 8 (IQR:10) months, total body CT scans showed no pleural disease progression or MPE recurrence in any of the patients. However, five patients developed extrathoracic disease progression (<xref rid="mps-08-00051-t003" ref-type="table">Table 3</xref>).</p></sec><sec sec-type="discussion" id="sec4-mps-08-00051"><title>4. Discussion</title><p>Only limited clinical data are available on the efficacy of intrathoracic aerosol chemotherapy using PITAC, primarily from a few case series [<xref rid="B10-mps-08-00051" ref-type="bibr">10</xref>,<xref rid="B27-mps-08-00051" ref-type="bibr">27</xref>,<xref rid="B28-mps-08-00051" ref-type="bibr">28</xref>,<xref rid="B29-mps-08-00051" ref-type="bibr">29</xref>,<xref rid="B30-mps-08-00051" ref-type="bibr">30</xref>,<xref rid="B31-mps-08-00051" ref-type="bibr">31</xref>]. The PITAC procedure was adapted from abdominal surgery, specifically from Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). PIPAC was introduced for the management of unresectable PtM in end-stage patients, where it achieved encouraging outcomes in histological tumor regression and effective ascites control, while preserving quality of life (QoL) [<xref rid="B11-mps-08-00051" ref-type="bibr">11</xref>,<xref rid="B32-mps-08-00051" ref-type="bibr">32</xref>]. The procedure has demonstrated safety and feasibility, with minimal postoperative complications and low systemic toxicity [<xref rid="B33-mps-08-00051" ref-type="bibr">33</xref>].</p><p>Given the promising results of PIPAC and the lack of alternative treatments for patients with PC-NSCLC and MPE, we designed a pilot study to evaluate the feasibility and oncological potential of PITAC as a thoracic adaptation of PIPAC.</p><p>PITAC involves the nebulization of aerosolized chemotherapy within the thoracic cavity during standard thoracoscopy. The rationale is based on physical principles: aerosol particles are evenly distributed in a closed space, and the pressure gradient enhances drug penetration by overcoming tumor interstitial pressure. Compared to liquid solutions, aerosols offer a higher surface area-to-volume ratio, facilitating deeper tissue penetration at higher local drug concentrations [<xref rid="B13-mps-08-00051" ref-type="bibr">13</xref>]. Additionally, chemotherapeutics with sclerosing properties can induce uniform pleurodesis, potentially alleviating MPE-related symptoms. This minimally invasive approach allows for repeatability, low morbidity, and improved QoL [<xref rid="B12-mps-08-00051" ref-type="bibr">12</xref>]. PITAC, like PIPAC, has also proven safe in terms of occupational exposure, with no evidence of OR contamination by aerosolized drugs [<xref rid="B33-mps-08-00051" ref-type="bibr">33</xref>].</p><p>PITAC was first performed in 2012 by Reymond in Herne, Germany, in combination with PIPAC for patients with pleural and peritoneal metastases from various origins, including gastric, ovarian, and mesothelioma [<xref rid="B30-mps-08-00051" ref-type="bibr">30</xref>]. However, the patient group was highly heterogeneous.</p><p>Our study is the first to focus exclusively on PC-NSCLC patients with MPE, treated by specialized thoracic surgeons. The preliminary results are encouraging and align with findings from the few available series [<xref rid="B27-mps-08-00051" ref-type="bibr">27</xref>,<xref rid="B30-mps-08-00051" ref-type="bibr">30</xref>,<xref rid="B31-mps-08-00051" ref-type="bibr">31</xref>]. PITAC proved technically feasible and safe in our cohort. All patients tolerated the procedure well. No intraoperative complications occurred, no postoperative complications of CTCAE grade &#x0003e;3 were observed, and 30-day mortality was zero, findings consistent with earlier PITAC and PIPAC reports [<xref rid="B29-mps-08-00051" ref-type="bibr">29</xref>,<xref rid="B30-mps-08-00051" ref-type="bibr">30</xref>,<xref rid="B31-mps-08-00051" ref-type="bibr">31</xref>]. In contrast, Kuchen et al. described a more heterogeneous group, including advanced stages of different tumors. Only four patients received PITAC for isolated MPE, while six underwent combined PITAC and PIPAC for abdominal carcinomatosis. Their series reported one intraoperative bowel injury (during PIPAC), a 14.7% rate of postoperative complications, including two prolonged air leaks after PITAC, a longer hospital stay (8.5 &#x000b1; 8.0 days vs. 5.4 &#x000b1; 4.7 in our series), and a high 30-day mortality rate of 28.6% [<xref rid="B29-mps-08-00051" ref-type="bibr">29</xref>].</p><p>Regarding the chemotherapeutic regimen, previous studies used only cisplatin (10.5 mg/m<sup>2</sup>) and doxorubicin (2.1 mg/m<sup>2</sup>), based on a dose-escalation study for intraperitoneal chemotherapy in recurrent ovarian cancer with PtM [<xref rid="B10-mps-08-00051" ref-type="bibr">10</xref>,<xref rid="B30-mps-08-00051" ref-type="bibr">30</xref>,<xref rid="B31-mps-08-00051" ref-type="bibr">31</xref>,<xref rid="B34-mps-08-00051" ref-type="bibr">34</xref>]. We selected the same combination due to its established efficacy, favorable local pharmacokinetics, and frequent use in regional chemotherapy protocols. Cisplatin offers strong cytotoxic activity with low systemic absorption, while doxorubicin enhances tumor penetration and synergizes with cisplatin [<xref rid="B35-mps-08-00051" ref-type="bibr">35</xref>,<xref rid="B36-mps-08-00051" ref-type="bibr">36</xref>]. This combination has shown promising results in intrathoracic chemotherapy [<xref rid="B8-mps-08-00051" ref-type="bibr">8</xref>,<xref rid="B37-mps-08-00051" ref-type="bibr">37</xref>]. Carboplatin, by contrast, has demonstrated lower efficacy in aerosol applications [<xref rid="B38-mps-08-00051" ref-type="bibr">38</xref>]. We corroborate the administration of platinum-based drugs and anthracyclines because, in addition to direct cytotoxic and cytostatic effects, both cisplatin and doxorubicin possess sclerosing properties that contribute to pleural cavity obliteration by inducing fibrinous pleuritis, thereby reducing MPE recurrence [<xref rid="B39-mps-08-00051" ref-type="bibr">39</xref>]. As evidence of the facts, in our series, pleurodesis was achieved in all patients and remained effective for over six months. No pleural disease progression or MPE recurrence was observed on FUP imaging. However, all patients also received systemic treatments (chemotherapy, ICIs, or TKIs), making it difficult to isolate PITAC&#x02019;s effect. Despite this, five of seven patients developed extrathoracic disease progression (three of whom were stage IVA&#x02014;M1b at diagnosis) suggesting PITAC may have contributed significantly to locoregional disease control. These findings advocate for further evaluation of its potential systemic cytotoxic effects.</p><p>Conversely, the role of HITHOC in managing MPE remains limited [<xref rid="B6-mps-08-00051" ref-type="bibr">6</xref>,<xref rid="B9-mps-08-00051" ref-type="bibr">9</xref>]. HITHOC is usually employed alongside cytoreductive surgery (e.g., pleurectomy/decortication) or after resection of primary tumors like lung cancer, thymoma, and thymic carcinoma. These approaches are typically reserved for patients eligible for extensive surgical resections and are applied with curative intent in the context of resectable disease [<xref rid="B8-mps-08-00051" ref-type="bibr">8</xref>]. In contrast, the PITAC procedure leverages aerosolized drug delivery and CO<sub>2</sub>-induced intrapleural pressure to enhance drug distribution and tumor penetration. This method allows for lower doses of chemotherapeutic agents compared to HITHOC, thereby minimizing systemic absorption and reducing associated toxicities [<xref rid="B9-mps-08-00051" ref-type="bibr">9</xref>,<xref rid="B29-mps-08-00051" ref-type="bibr">29</xref>]. Therefore, PITAC represents a promising therapeutic option for patients who are unfit for radical surgery, offering a minimally invasive approach to achieve local tumor control with reduced systemic toxicity and improved tolerability.</p><p>To our knowledge, this is the first study focused on PITAC for PC-NSCLC, with or without MPE. To validate our findings, we also developed an in vitro model using primary cell cultures derived from patient tumor samples to evaluate PITAC&#x02019;s antineoplastic activity.</p><p>Despite the small sample size, results from the 2D cultures obtained immediately post-PITAC were notable. No viable tumor cell growth was observed, demonstrating the cytotoxic and antiproliferative effect of pressurized aerosol chemotherapy.</p><p>No prior study has evaluated PITAC in vitro or in vivo for PC-NSCLC. Patient-derived primary cultures are a reliable preclinical model, closely mimicking the original tumor tissue [<xref rid="B14-mps-08-00051" ref-type="bibr">14</xref>,<xref rid="B15-mps-08-00051" ref-type="bibr">15</xref>]. Numerous studies have confirmed that in vitro chemosensitivity often correlates with clinical outcomes, suggesting these models may help personalize treatment in advanced-stage NSCLC. Personalized medicine approaches could benefit from treating patient-derived cultures with the same agents used in vivo, potentially guiding individualized therapy selection [<xref rid="B24-mps-08-00051" ref-type="bibr">24</xref>,<xref rid="B25-mps-08-00051" ref-type="bibr">25</xref>,<xref rid="B26-mps-08-00051" ref-type="bibr">26</xref>].</p><p>We also highlight the multidisciplinary approach of our study, which integrates clinical and radiological evaluation with in vitro testing of the chemotherapeutic regimen. Our preliminary results are promising and lay the groundwork for future studies using patient-derived tumor cells to optimize PITAC. A dose-escalation analysis of cisplatin and doxorubicin using an in vitro model that replicates PITAC will help define the most effective concentrations. A minimum enrollment of 30 patients is expected over the next 3 years in this ongoing phase 2 study. In the near future, this translational model could be adopted to test in vitro and/or in vivo chemosensitivity of patient&#x02019;s tumor cells against a range of different potential therapeutic agents to select the best option and combination for each patient on a personalized basis.</p><p>Meanwhile, some limitations should be acknowledged; first, the small sample size and the absence of a control group should be considered when interpreting the study results. On the other hand, in the present work, we reported the preliminary results of a more extensive pilot study, which is still ongoing. In addition, PITAC is a new procedure, and our results should be independently confirmed. The requirement for environmental precautions may also be a limitation and further investigation is needed to justify wider use of PITAC, particularly compared to less complex methods. Neither survival probability nor predictive factors were evaluated because statistical significance could not be obtained according to the underpowered sample size. Lastly, the non-randomized design could limit the generalizability of the results because the selection bias might influence favorably for PITAC. Future randomized controlled trials are needed to validate our findings.</p></sec><sec sec-type="conclusions" id="sec5-mps-08-00051"><title>5. Conclusions</title><p>This pilot study demonstrated the feasibility, safety, and efficacy of PITAC in inducing palliative pleurodesis, with promising outcomes regarding local antineoplastic control. The absence of intraoperative complications, low morbidity, and effective pleurodesis at various time points underscore the potential of PITAC in revolutionizing loco-regional therapy for PC-NSCLC.</p><p>While the complexity of pleural metastases may limit PITAC&#x02019;s efficacy, several aspects support its potential. PITAC ensures homogeneous aerosol distribution under pressure, enhancing drug penetration beyond superficial layers. In early pleural dissemination, lesions are often superficial, making PITAC particularly suitable. Preclinical data confirm aerosol infiltration into deeper tissue. PITAC also complements systemic therapies, offering synergistic local control. It should thus be considered part of a broader multimodal treatment strategy.</p><p>An in vivo and in vitro validation of this technique could pave the way for a new approach to managing these particularly frail metastatic patients, as the ability to locally administer chemotherapy may change the natural history of the disease without causing systemic side effects. Furthermore, due to its relatively low cost, PITAC may represent a highly sustainable procedure in terms of both clinical outcomes and socio-economic impact on the healthcare system.</p><p>As the first report focused exclusively on PC-NSCLC, this work lays the groundwork for future investigations, encouraging the pursuit of personalized medicine approaches and advancing the field of loco-regional therapy for thoracic malignancies with larger, controlled trials to validate the observed outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-mps-08-00051"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/mps8030051/s1">https://www.mdpi.com/article/10.3390/mps8030051/s1</uri>, Supplemental File S1: The CONSORT checklist.</p><supplementary-material id="mps-08-00051-s001" position="float" content-type="local-data"><media xlink:href="mps-08-00051-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: M.G.M. and V.A.; data curation: A.L., G.E. and D.B.; formal analysis: M.G.M., V.A., D.B. and M.C.A.; funding acquisition: NA; investigation: A.L., G.E. and S.K.; methodology: M.G.M., V.A., A.L. and P.F.; project administration: M.G.M., M.L. and P.F.; resources: M.G.M., S.M.F., A.L. and G.E.; software: D.B. and S.K.; supervision: M.G.M., V.A., S.M.F. and M.L.; validation: M.L., M.C.A. and P.F.; visualization: S.K., S.M.F., M.C.A., P.F. and M.L.; writing&#x02014;original draft: M.G.M., V.A. and G.E.; writing&#x02014;review and editing: all the authors. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of University Hospital of Pisa (approval number: CEAVNO12062022). The study protocol was registered in the Clinical Trial Information System (CTIS); EuCT No: 2024-511255-17-00; <uri xlink:href="https://euclinicaltrials.eu">https://euclinicaltrials.eu</uri> (accessed on 13 May 2025).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The article&#x02019;s underlying data will be shared on reasonable request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-mps-08-00051"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>American Society of Clinical Oncology</collab>
</person-group><article-title>Cancer.Net: Lung Cancer-Non-Small Cell: Statistics (Approved by the Cancer.Net Editorial Board, 29 January 2024)</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics" ext-link-type="uri">https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-26">(accessed on 26 October 2024)</date-in-citation></element-citation></ref><ref id="B2-mps-08-00051"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Q.</given-names></name>
<name><surname>Deng</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<name><surname>Qi</surname><given-names>C.</given-names></name>
<name><surname>Tan</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Pu</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: A retrospective multicenter study</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><elocation-id>393</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-024-12173-1</pub-id><pub-id pub-id-type="pmid">38549044</pub-id>
</element-citation></ref><ref id="B3-mps-08-00051"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>National Comprehensive Cancer Network</collab>
</person-group><article-title>NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer; Version 4.2023&#x02014;18 October 2023</article-title><comment>Available online: <ext-link xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-10-26">(accessed on 26 October 2023)</date-in-citation></element-citation></ref><ref id="B4-mps-08-00051"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bibby</surname><given-names>A.C.</given-names></name>
<name><surname>Dorn</surname><given-names>P.</given-names></name>
<name><surname>Psallidas</surname><given-names>I.</given-names></name>
<name><surname>Porcel</surname><given-names>J.M.</given-names></name>
<name><surname>Janssen</surname><given-names>J.</given-names></name>
<name><surname>Froudarakis</surname><given-names>M.</given-names></name>
<name><surname>Subotic</surname><given-names>D.</given-names></name>
<name><surname>Astoul</surname><given-names>P.</given-names></name>
<name><surname>Licht</surname><given-names>P.</given-names></name>
<name><surname>Schmid</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>ERS/EACTS statement on the management of malignant pleural effusions</article-title><source>Eur. J. Cardiothorac. Surg.</source><year>2019</year><volume>55</volume><fpage>116</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezy258</pub-id><pub-id pub-id-type="pmid">30060030</pub-id>
</element-citation></ref><ref id="B5-mps-08-00051"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>M.E.</given-names></name>
<name><surname>Rahman</surname><given-names>N.M.</given-names></name>
<name><surname>Maskell</surname><given-names>N.A.</given-names></name>
<name><surname>Bibby</surname><given-names>A.C.</given-names></name>
<name><surname>Blyth</surname><given-names>K.G.</given-names></name>
<name><surname>Corcoran</surname><given-names>J.P.</given-names></name>
<name><surname>Edey</surname><given-names>A.</given-names></name>
<name><surname>Evison</surname><given-names>M.</given-names></name>
<name><surname>de Fonseka</surname><given-names>D.</given-names></name>
<name><surname>Hallifax</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>British Thoracic Society Guideline for pleural disease</article-title><source>Thorax</source><year>2023</year><volume>78</volume><issue>(Suppl. 3)</issue><fpage>S1</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1136/thorax-2022-219784</pub-id></element-citation></ref><ref id="B6-mps-08-00051"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>e5532</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000005532</pub-id><pub-id pub-id-type="pmid">28072694</pub-id>
</element-citation></ref><ref id="B7-mps-08-00051"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>H.</given-names></name>
<name><surname>Meng</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion</article-title><source>Thorac. Cancer</source><year>2018</year><volume>9</volume><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.12582</pub-id><pub-id pub-id-type="pmid">29297985</pub-id>
</element-citation></ref><ref id="B8-mps-08-00051"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aprile</surname><given-names>V.</given-names></name>
<name><surname>Lenzini</surname><given-names>A.</given-names></name>
<name><surname>Lococo</surname><given-names>F.</given-names></name>
<name><surname>Bacchin</surname><given-names>D.</given-names></name>
<name><surname>Korasidis</surname><given-names>S.</given-names></name>
<name><surname>Mastromarino</surname><given-names>M.G.</given-names></name>
<name><surname>Guglielmi</surname><given-names>G.</given-names></name>
<name><surname>Palmiero</surname><given-names>G.</given-names></name>
<name><surname>Ambrogi</surname><given-names>M.C.</given-names></name>
<name><surname>Lucchi</surname><given-names>M.</given-names></name>
</person-group><article-title>Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment</article-title><source>J. Clin. Med.</source><year>2021</year><volume>10</volume><elocation-id>3801</elocation-id><pub-id pub-id-type="doi">10.3390/jcm10173801</pub-id><pub-id pub-id-type="pmid">34501249</pub-id>
</element-citation></ref><ref id="B9-mps-08-00051"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>K.</given-names></name>
<name><surname>Flores</surname><given-names>R.M.</given-names></name>
</person-group><article-title>A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer</article-title><source>Ann. Transl. Med.</source><year>2021</year><volume>9</volume><fpage>958</fpage><pub-id pub-id-type="doi">10.21037/atm-20-6514</pub-id><pub-id pub-id-type="pmid">34350273</pub-id>
</element-citation></ref><ref id="B10-mps-08-00051"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drevet</surname><given-names>G.</given-names></name>
<name><surname>Maury</surname><given-names>J.M.</given-names></name>
<name><surname>Bakrin</surname><given-names>N.</given-names></name>
<name><surname>Tronc</surname><given-names>F.</given-names></name>
</person-group><article-title>Technique of pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural effusion</article-title><source>Pleura Peritoneum</source><year>2020</year><volume>5</volume><fpage>20200129</fpage><pub-id pub-id-type="doi">10.1515/pp-2020-0129</pub-id><pub-id pub-id-type="pmid">33575461</pub-id>
</element-citation></ref><ref id="B11-mps-08-00051"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solass</surname><given-names>W.</given-names></name>
<name><surname>Kerb</surname><given-names>R.</given-names></name>
<name><surname>M&#x000fc;rdter</surname><given-names>T.</given-names></name>
<name><surname>Giger-Pabst</surname><given-names>U.</given-names></name>
<name><surname>Strumberg</surname><given-names>D.</given-names></name>
<name><surname>Tempfer</surname><given-names>C.</given-names></name>
<name><surname>Zieren</surname><given-names>J.</given-names></name>
<name><surname>Schwab</surname><given-names>M.</given-names></name>
<name><surname>Reymond</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy</article-title><source>Ann. Surg. Oncol.</source><year>2014</year><volume>21</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3213-1</pub-id><pub-id pub-id-type="pmid">24006094</pub-id>
</element-citation></ref><ref id="B12-mps-08-00051"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robella</surname><given-names>M.</given-names></name>
<name><surname>Vaira</surname><given-names>M.</given-names></name>
<name><surname>De Simone</surname><given-names>M.</given-names></name>
</person-group><article-title>Safety and feasibility of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis</article-title><source>World J. Surg. Oncol.</source><year>2016</year><volume>14</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s12957-016-0892-7</pub-id><pub-id pub-id-type="pmid">27125996</pub-id>
</element-citation></ref><ref id="B13-mps-08-00051"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solass</surname><given-names>W.</given-names></name>
<name><surname>Herbette</surname><given-names>A.</given-names></name>
<name><surname>Schwarz</surname><given-names>T.</given-names></name>
<name><surname>Hetzel</surname><given-names>A.</given-names></name>
<name><surname>Sun</surname><given-names>J.-S.</given-names></name>
<name><surname>Dutreix</surname><given-names>M.</given-names></name>
<name><surname>Reymond</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept</article-title><source>Surg. Endosc.</source><year>2012</year><volume>26</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1007/s00464-011-1964-y</pub-id><pub-id pub-id-type="pmid">22042585</pub-id>
</element-citation></ref><ref id="B14-mps-08-00051"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazzocchi</surname><given-names>A.</given-names></name>
<name><surname>Devarasetty</surname><given-names>M.</given-names></name>
<name><surname>Herberg</surname><given-names>S.</given-names></name>
<name><surname>Petty</surname><given-names>W.J.</given-names></name>
<name><surname>Marini</surname><given-names>F.</given-names></name>
<name><surname>Miller</surname><given-names>L.</given-names></name>
<name><surname>Kucera</surname><given-names>G.</given-names></name>
<name><surname>Dukes</surname><given-names>D.K.</given-names></name>
<name><surname>Ruiz</surname><given-names>J.</given-names></name>
<name><surname>Skardal</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening</article-title><source>ACS Biomater. Sci. Eng.</source><year>2019</year><volume>5</volume><fpage>1937</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b01356</pub-id><pub-id pub-id-type="pmid">31723594</pub-id>
</element-citation></ref><ref id="B15-mps-08-00051"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz</surname><given-names>C.</given-names></name>
<name><surname>Kustermann</surname><given-names>S.</given-names></name>
<name><surname>Pietilae</surname><given-names>E.</given-names></name>
<name><surname>Vlajnic</surname><given-names>T.</given-names></name>
<name><surname>Baschiera</surname><given-names>B.</given-names></name>
<name><surname>Arabi</surname><given-names>L.</given-names></name>
<name><surname>Lorber</surname><given-names>T.</given-names></name>
<name><surname>Oeggerli</surname><given-names>M.</given-names></name>
<name><surname>Savic</surname><given-names>S.</given-names></name>
<name><surname>Obermann</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160807</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160807</pub-id><pub-id pub-id-type="pmid">27548442</pub-id>
</element-citation></ref><ref id="B16-mps-08-00051"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oken</surname><given-names>M.M.</given-names></name>
<name><surname>Creech</surname><given-names>R.H.</given-names></name>
<name><surname>Tormey</surname><given-names>D.C.</given-names></name>
<name><surname>Horton</surname><given-names>J.</given-names></name>
<name><surname>Davis</surname><given-names>T.E.</given-names></name>
<name><surname>McFadden</surname><given-names>E.T.</given-names></name>
<name><surname>Carbone</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title><source>Am. J. Clin. Oncol.</source><year>1982</year><volume>5</volume><fpage>649</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1097/00000421-198212000-00014</pub-id><pub-id pub-id-type="pmid">7165009</pub-id>
</element-citation></ref><ref id="B17-mps-08-00051"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Detterbeck</surname><given-names>F.C.</given-names></name>
<name><surname>Chansky</surname><given-names>K.</given-names></name>
<name><surname>Groome</surname><given-names>P.</given-names></name>
<name><surname>Bolejack</surname><given-names>V.</given-names></name>
<name><surname>Crowley</surname><given-names>J.</given-names></name>
<name><surname>Shemanski</surname><given-names>L.</given-names></name>
<name><surname>Kennedy</surname><given-names>C.</given-names></name>
<name><surname>Krasnik</surname><given-names>M.</given-names></name>
<name><surname>Peake</surname><given-names>M.</given-names></name>
<name><surname>Goldstraw</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: Methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer</article-title><source>J. Thorac. Oncol.</source><year>2016</year><volume>11</volume><fpage>1433</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.06.028</pub-id><pub-id pub-id-type="pmid">27448762</pub-id>
</element-citation></ref><ref id="B18-mps-08-00051"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazumdar</surname><given-names>M.</given-names></name>
<name><surname>Smith</surname><given-names>A.</given-names></name>
<name><surname>Schwartz</surname><given-names>L.H.</given-names></name>
</person-group><article-title>A statistical simulation study finds discordance between WHO criteria and RECIST guideline</article-title><source>J. Clin. Epidemiol.</source><year>2004</year><volume>57</volume><fpage>358</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.07.015</pub-id><pub-id pub-id-type="pmid">15135836</pub-id>
</element-citation></ref><ref id="B19-mps-08-00051"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>US Department of Health and Human Services</collab>
</person-group><source>Common Terminology Criteria for Adverse Events, Version 5.0</source><publisher-name>US Department of Health and Human Services</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B20-mps-08-00051"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schulz</surname><given-names>K.F.</given-names></name>
<name><surname>Altman</surname><given-names>D.G.</given-names></name>
<name><surname>Moher</surname><given-names>D.</given-names></name>
<collab>CONSORT Group</collab>
</person-group><article-title>CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials</article-title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>c332</fpage><pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id><pub-id pub-id-type="pmid">20332509</pub-id>
</element-citation></ref><ref id="B21-mps-08-00051"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eisenhauer</surname><given-names>E.A.</given-names></name>
<name><surname>Therasse</surname><given-names>P.</given-names></name>
<name><surname>Bogaerts</surname><given-names>J.</given-names></name>
<name><surname>Schwartz</surname><given-names>L.H.</given-names></name>
<name><surname>Sargent</surname><given-names>D.</given-names></name>
<name><surname>Ford</surname><given-names>R.</given-names></name>
<name><surname>Dancey</surname><given-names>J.</given-names></name>
<name><surname>Arbuck</surname><given-names>S.</given-names></name>
<name><surname>Gwyther</surname><given-names>S.</given-names></name>
<name><surname>Mooney</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</article-title><source>Eur. J. Cancer</source><year>2009</year><volume>45</volume><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id>
</element-citation></ref><ref id="B22-mps-08-00051"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Boyd</surname><given-names>E.</given-names></name>
</person-group><source>The Growth of the Surface Area of the Human Body</source><series>Institute of Child Welfare, Monograph Series 10</series><publisher-name>University of Minnesota Press</publisher-name><publisher-loc>Minneapolis, MN, USA</publisher-loc><year>1935</year></element-citation></ref><ref id="B23-mps-08-00051"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Ermis</surname><given-names>R.</given-names></name>
<name><surname>Garcia</surname><given-names>A.</given-names></name>
<name><surname>Telgenhoff</surname><given-names>D.</given-names></name>
<name><surname>Aust</surname><given-names>D.</given-names></name>
</person-group><article-title>Degradation of human collagen isoforms by Clostridium collagenase and the effects of degradation products on cell migration</article-title><source>Int. Wound J.</source><year>2010</year><volume>7</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1111/j.1742-481X.2010.00659.x</pub-id><pub-id pub-id-type="pmid">20529148</pub-id>
</element-citation></ref><ref id="B24-mps-08-00051"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zoli</surname><given-names>W.</given-names></name>
<name><surname>Ricotti</surname><given-names>L.</given-names></name>
<name><surname>Susino</surname><given-names>M.D.</given-names></name>
<name><surname>Barzanti</surname><given-names>F.</given-names></name>
<name><surname>Frassineti</surname><given-names>G.L.</given-names></name>
<name><surname>Folli</surname><given-names>S.</given-names></name>
<name><surname>Tesei</surname><given-names>A.</given-names></name>
<name><surname>Bacci</surname><given-names>F.</given-names></name>
<name><surname>Amadori</surname><given-names>D.</given-names></name>
</person-group><article-title>Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer</article-title><source>Br. J. Cancer</source><year>1999</year><volume>81</volume><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6690737</pub-id><pub-id pub-id-type="pmid">10574245</pub-id>
</element-citation></ref><ref id="B25-mps-08-00051"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fallahi</surname><given-names>P.</given-names></name>
<name><surname>Ferrari</surname><given-names>S.M.</given-names></name>
<name><surname>Elia</surname><given-names>G.</given-names></name>
<name><surname>Ragusa</surname><given-names>F.</given-names></name>
<name><surname>Patrizio</surname><given-names>A.</given-names></name>
<name><surname>Paparo</surname><given-names>S.R.</given-names></name>
<name><surname>Marone</surname><given-names>G.</given-names></name>
<name><surname>Galdiero</surname><given-names>M.R.</given-names></name>
<name><surname>Guglielmi</surname><given-names>G.</given-names></name>
<name><surname>Foddis</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin</article-title><source>Semin Cancer Biol.</source><year>2022</year><volume>79</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.06.013</pub-id><pub-id pub-id-type="pmid">32569821</pub-id>
</element-citation></ref><ref id="B26-mps-08-00051"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antonelli</surname><given-names>A.</given-names></name>
<name><surname>Ferrari</surname><given-names>S.M.</given-names></name>
<name><surname>Fallahi</surname><given-names>P.</given-names></name>
<name><surname>Berti</surname><given-names>P.</given-names></name>
<name><surname>Materazzi</surname><given-names>G.</given-names></name>
<name><surname>Marchetti</surname><given-names>I.</given-names></name>
<name><surname>Ugolini</surname><given-names>C.</given-names></name>
<name><surname>Basolo</surname><given-names>F.</given-names></name>
<name><surname>Miccoli</surname><given-names>P.</given-names></name>
<name><surname>Ferrannini</surname><given-names>E.</given-names></name>
</person-group><article-title>Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration</article-title><source>Eur. J. Endocrinol.</source><year>2008</year><volume>159</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1530/EJE-08-0190</pub-id><pub-id pub-id-type="pmid">18583391</pub-id>
</element-citation></ref><ref id="B27-mps-08-00051"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>P.S.</given-names></name>
<name><surname>Graversen</surname><given-names>M.</given-names></name>
<name><surname>Detlefsen</surname><given-names>S.</given-names></name>
<name><surname>Mortensen</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Review on treatment of pleural metastasis and malignant pleural effusion with Pressurized IntraThoracic Aerosol Chemotherapy (PITAC)</article-title><source>Pleura Peritoneum</source><year>2024</year><volume>9</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1515/pp-2023-0048</pub-id><pub-id pub-id-type="pmid">38948327</pub-id>
</element-citation></ref><ref id="B28-mps-08-00051"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mastromarino</surname><given-names>M.G.</given-names></name>
<name><surname>Calabr&#x000f2;</surname><given-names>F.</given-names></name>
<name><surname>Elia</surname><given-names>G.</given-names></name>
<name><surname>Bacchin</surname><given-names>D.</given-names></name>
<name><surname>Aprile</surname><given-names>V.</given-names></name>
<name><surname>Korasidis</surname><given-names>S.</given-names></name>
<name><surname>Ambrogi</surname><given-names>M.C.</given-names></name>
<name><surname>Lucchi</surname><given-names>M.</given-names></name>
</person-group><article-title>Pressurized Intra-Thoracic Aerosol Chemotherapy (PITAC): Preliminary results in malignant pleural effusion</article-title><source>Eur. Respir. J.</source><year>2023</year><volume>62</volume><issue>(Suppl. 67)</issue><fpage>OA1564</fpage><pub-id pub-id-type="doi">10.1183/13993003.congress-2023.OA1564</pub-id></element-citation></ref><ref id="B29-mps-08-00051"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuchen</surname><given-names>N.</given-names></name>
<name><surname>Cereser</surname><given-names>T.</given-names></name>
<name><surname>Hailemariam</surname><given-names>S.</given-names></name>
<name><surname>Schoeb</surname><given-names>O.</given-names></name>
</person-group><article-title>Safety and efficacy of pressurized intraperitoneal/intrathoracic aerosol chemotherapy (PIPAC/PITAC) in patients with peritoneal and/or pleural carcinomatosis: A preliminary experience</article-title><source>J. Med. Therap.</source><year>2018</year><volume>2</volume><fpage>1000127</fpage><pub-id pub-id-type="doi">10.15761/JMT.1000127</pub-id></element-citation></ref><ref id="B30-mps-08-00051"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robella</surname><given-names>M.</given-names></name>
<name><surname>Vaira</surname><given-names>M.</given-names></name>
<name><surname>Borsano</surname><given-names>A.</given-names></name>
<name><surname>Mossetti</surname><given-names>C.</given-names></name>
<name><surname>DESimone</surname><given-names>M.</given-names></name>
</person-group><article-title>Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei</article-title><source>Anticancer Res.</source><year>2018</year><volume>38</volume><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.21873/anticanres.12305</pub-id><pub-id pub-id-type="pmid">29374723</pub-id>
</element-citation></ref><ref id="B31-mps-08-00051"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Jonscher</surname><given-names>N.</given-names></name>
<name><surname>Hummels</surname><given-names>M.</given-names></name>
<name><surname>Giger-Pabst</surname><given-names>U.</given-names></name>
<name><surname>Karljalainen</surname><given-names>E.</given-names></name>
<name><surname>Zieren</surname><given-names>J.</given-names></name>
<name><surname>B&#x000fc;chner</surname><given-names>N.</given-names></name>
</person-group><article-title>Pressurized IntraThoracic Aerosol Chemotherapy (PITAC)</article-title><source>Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): Cancer under Pressure</source><person-group person-group-type="editor">
<name><surname>Reymond</surname><given-names>M.N.A.</given-names></name>
<name><surname>Solass</surname><given-names>W.</given-names></name>
</person-group><publisher-name>De Gruyter</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><publisher-loc>Boston, MA, USA</publisher-loc><year>2014</year><fpage>183</fpage><lpage>186</lpage></element-citation></ref><ref id="B32-mps-08-00051"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solass</surname><given-names>W.</given-names></name>
<name><surname>Sempoux</surname><given-names>C.</given-names></name>
<name><surname>Detlefsen</surname><given-names>S.</given-names></name>
<name><surname>Carr</surname><given-names>N.J.</given-names></name>
<name><surname>Bibeau</surname><given-names>F.</given-names></name>
</person-group><article-title>Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: Proposal of the Peritoneal Regression Grading Score (PRGS)</article-title><source>Pleura Peritoneum</source><year>2016</year><volume>1</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1515/pp-2016-0011</pub-id><pub-id pub-id-type="pmid">30911613</pub-id>
</element-citation></ref><ref id="B33-mps-08-00051"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solass</surname><given-names>W.</given-names></name>
<name><surname>Giger-Pabst</surname><given-names>U.</given-names></name>
<name><surname>Zieren</surname><given-names>J.</given-names></name>
<name><surname>Reymond</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects</article-title><source>Ann. Surg. Oncol.</source><year>2013</year><volume>20</volume><fpage>3504</fpage><lpage>3511</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3039-x</pub-id><pub-id pub-id-type="pmid">23765417</pub-id>
</element-citation></ref><ref id="B34-mps-08-00051"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tempfer</surname><given-names>C.B.</given-names></name>
<name><surname>Giger-Pabst</surname><given-names>U.</given-names></name>
<name><surname>Seebacher</surname><given-names>V.</given-names></name>
<name><surname>Petersen</surname><given-names>M.</given-names></name>
<name><surname>Dogan</surname><given-names>A.</given-names></name>
<name><surname>Rezniczek</surname><given-names>G.A.</given-names></name>
</person-group><article-title>A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis</article-title><source>Gynecol. Oncol.</source><year>2018</year><volume>150</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2018.05.001</pub-id><pub-id pub-id-type="pmid">29743140</pub-id>
</element-citation></ref><ref id="B35-mps-08-00051"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugarbaker</surname><given-names>D.J.</given-names></name>
<name><surname>Jaklitsch</surname><given-names>M.T.</given-names></name>
<name><surname>Bueno</surname><given-names>R.</given-names></name>
<name><surname>Richards</surname><given-names>W.</given-names></name>
<name><surname>Lukanich</surname><given-names>J.</given-names></name>
<name><surname>Mentzer</surname><given-names>S.J.</given-names></name>
<name><surname>Colson</surname><given-names>Y.</given-names></name>
<name><surname>Linden</surname><given-names>P.</given-names></name>
<name><surname>Chang</surname><given-names>M.</given-names></name>
<name><surname>Capalbo</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies</article-title><source>J. Thorac. Cardiovasc. Surg.</source><year>2004</year><volume>128</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2004.02.021</pub-id><pub-id pub-id-type="pmid">15224033</pub-id>
</element-citation></ref><ref id="B36-mps-08-00051"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Markman</surname><given-names>M.</given-names></name>
</person-group><article-title>Intraperitoneal antineoplastic drug delivery: Rationale and results</article-title><source>Lancet Oncol.</source><year>2001</year><volume>2</volume><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(03)01074-X</pub-id><pub-id pub-id-type="pmid">12732164</pub-id>
</element-citation></ref><ref id="B37-mps-08-00051"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>P.S.</given-names></name>
<name><surname>Graversen</surname><given-names>M.</given-names></name>
<name><surname>Detlefsen</surname><given-names>S.</given-names></name>
<name><surname>Ainsworth</surname><given-names>A.P.</given-names></name>
<name><surname>Fristrup</surname><given-names>C.W.</given-names></name>
<name><surname>Eckhoff</surname><given-names>L.</given-names></name>
<name><surname>Jelin-Klaric</surname><given-names>M.</given-names></name>
<name><surname>Mortensen</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in patients with malignant pleural effusion: Study protocol for the Danish phase-I PITAC-OPC5 study</article-title><source>Pleura Peritoneum</source><year>2024</year><volume>9</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1515/pp-2024-0014</pub-id><pub-id pub-id-type="pmid">39712295</pub-id>
</element-citation></ref><ref id="B38-mps-08-00051"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alberts</surname><given-names>D.S.</given-names></name>
<name><surname>Muggia</surname><given-names>F.M.</given-names></name>
<name><surname>Carmichael</surname><given-names>J.</given-names></name>
<name><surname>Parnes</surname><given-names>H.</given-names></name>
<name><surname>Dodion</surname><given-names>P.</given-names></name>
<name><surname>Gertz</surname><given-names>B.</given-names></name>
</person-group><article-title>Carboplatin versus cisplatin in ovarian cancer: Preliminary observations</article-title><source>Semin Oncol.</source><year>1995</year><volume>22</volume><issue>(Suppl. 9)</issue><fpage>61</fpage><lpage>67</lpage></element-citation></ref><ref id="B39-mps-08-00051"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishi</surname><given-names>K.</given-names></name>
<name><surname>Homma</surname><given-names>S.</given-names></name>
<name><surname>Sakamoto</surname><given-names>S.</given-names></name>
<name><surname>Kawabata</surname><given-names>M.</given-names></name>
<name><surname>Tsuboi</surname><given-names>E.</given-names></name>
<name><surname>Nakata</surname><given-names>K.</given-names></name>
<name><surname>Yoshimura</surname><given-names>K.</given-names></name>
</person-group><article-title>Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions</article-title><source>Eur. Respir. J.</source><year>2004</year><volume>24</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1183/09031936.04.00137403</pub-id><pub-id pub-id-type="pmid">15332395</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="mps-08-00051-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>) Patient in lateral decubitus position, with two 12 mm balloon trocars, one in the VII ICS in the mid-axillary line and the second one in the V ICS in the anterior axillary line. (<bold>B</bold>) Intraoperative view of 12 mm balloon trocar. (<bold>C</bold>) Intraoperative picture of parietal pleural biopsy. (<bold>D</bold>) CE-certified nebulizer and intra-thoracic nebulization of chemotherapeutic agents.</p></caption><graphic xlink:href="mps-08-00051-g001" position="float"/></fig><fig position="float" id="mps-08-00051-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) High-pressure injector connected to CE-certified nebulizer to consecutively aerosolize cisplatin and doxorubicin into the pleural cavity at 0.7 mL/s flow with a maximal upstream pressure of 1.517 &#x000d7; 10<sup>6</sup> Pa. (<bold>B</bold>) The nebulization procedure is remote-controlled from outside the operating room. (<bold>C</bold>) Intraoperative view of residual molecules of the toxic aerosol aspirated using a closed surgical smoke evacuation system. (<bold>D</bold>) Detail of surgical smoke evacuation system with two micro-particle filters.</p></caption><graphic xlink:href="mps-08-00051-g002" position="float"/></fig><fig position="float" id="mps-08-00051-f003"><label>Figure 3</label><caption><p>(<bold>A</bold>) Example of time 0 cell cultures formed confluent and mainly monolayer sheets of medium-sized attached tumor cells (magnification, 10&#x000d7;). (<bold>B</bold>) Example of time 30 min after PITAC cell cultures exhibited a significant reduction in cancer cell growth (magnification, 10&#x000d7;).</p></caption><graphic xlink:href="mps-08-00051-g003" position="float"/></fig><table-wrap position="float" id="mps-08-00051-t001"><object-id pub-id-type="pii">mps-08-00051-t001_Table 1</object-id><label>Table 1</label><caption><p>Patients&#x02019; pre-operative characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients (n; %)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;Gender</bold>
</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Male</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">4 (57%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Female</td><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x000a0;<bold>Median Age</bold> (years, IQR)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65 (19)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;ECOG score</bold>
</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;1</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;2</td><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">4 (57%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;Comorbidities</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;COPD</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Hypertensive heart disease</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (72%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Heavy smoking</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Cerebrovascular disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (28%)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;Stage <sup>a</sup></bold>
</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;IVA&#x02014;M1a</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">4 (57%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;IVA&#x02014;M1b (bone)</td><td align="left" valign="middle" style="border-bottom:solid thin;background:silver" rowspan="1" colspan="1">3 (43%)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: n, number; IQR, interquartile range; ECOG, Eastern Oncology Cooperative Group; COPD, chronic obstructive pulmonary disease; <sup>a</sup> according to the eight edition of TNM classification for lung cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="mps-08-00051-t002"><object-id pub-id-type="pii">mps-08-00051-t002_Table 2</object-id><label>Table 2</label><caption><p>Major immunohistochemical and molecular characteristics of lung adenocarcinomas.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients (n; %)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;TTF-1 (+)<break/>
&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;TTF-1 (&#x02212;)</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">6 (86%)<break/>1 (14%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;CK-7 (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;CK-7 (&#x02212;)</td><td align="left" valign="middle" rowspan="1" colspan="1">4 (57%)<break/>3 (43%)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;p40 (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;p40 (&#x02212;)</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">1 (14%)<break/>6 (86%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Calretinin (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Calretinin (&#x02212;)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (28%)<break/>5 (72%)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;CK-Pan (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;CK-Pan (&#x02212;)</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">4 (57%)<break/>3 (43%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Napsin A (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Napsin A (&#x02212;)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 (72%)<break/>2(28%)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;BerEP4 (+)<break/>&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;BerEP4 (&#x02212;)</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">5 (72%)<break/>2 (28%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;EGFR exon 19 deletion</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (28%)</td></tr><tr><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;KRAS G12D mutation</td><td align="left" valign="middle" style="background:silver" rowspan="1" colspan="1">2 (28%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;KRAS G12F mutation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (14%)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: n, number; (+), positivity; (&#x02212;) negativity; TTF-1, Thyroid Transcription Factor 1; CK, cytokeratin; EGFR, Epidermal Growth Factor Receptor; KRAS, Kirsten Rat Sarcoma Virus.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="mps-08-00051-t003"><object-id pub-id-type="pii">mps-08-00051-t003_Table 3</object-id><label>Table 3</label><caption><p>Treatment and disease progression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients (n; %)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;Site of disease progression</bold>
</td><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;None</td><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">2 (29%)</td></tr><tr><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Bone</td><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Brain</td><td align="left" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">1 (14%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin;background:#BFBFBF" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Liver</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#BFBFBF" rowspan="1" colspan="1">1 (14%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>&#x02003;&#x000a0;&#x000a0;Post-operative systemic therapy</bold>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Platinum-based CT + ICI (Pembrolizumab)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (43%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;Platinum-based CT + ICI (Pembrolizumab) + RT (bone)</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (14%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;TKI (Osimertinib)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 (29%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x000a0;&#x02003;&#x000a0;&#x02003;&#x000a0;&#x000a0;ICI (Atezolizumab) + second-line platinum-based CT *</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (14%)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: n, number; CT, chemotherapy; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor. * The only patient who underwent preoperative systemic therapy (with ICI, atezolizumab).</p></fn></table-wrap-foot></table-wrap></floats-group></article>